Article

Zejula May Improve Survival in Certain Ovarian Cancer Subgroups

Author(s):

Darlene Dobkowski, MA
Conference|ASCO Annual Meeting

Progression-free survival improved with Zejula compared with placebo in patients with BRCA-mutated ovarian cancer with no new safety signals.

Patients with BRCA-mutated ovarian cancer who underwent maintenance therapy with Zejula (niraparib) had significantly improved progression-free survival compared with those who received placebo, according to newly presented research.

“Patients with BRCA-mutated ovarian cancer derived a significant progression-free survival benefit from (Zejula) maintenance treatment across all three trials in first-line and recurrent settings after response to platinum-based chemotherapy,” said Dr. Antonio Gonzalez Martin, co-director of the department of medical oncology at Clinica Universidad de Navarra in Spain and president of the Spanish Ovarian Cancer Group (GEICO), during the poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Researchers assessed the efficacy and safety of Zejula compared with placebo in patients with BRCA mutated ovarian cancer from three trials: ENGOT-OV16/NOVA (203 patients), PRIMA/ENGOT-OV26/GOG-3012 (223 patients) and NORA (100 patients).

“BRCA mutations occur in approximately 20% to 25% of patients with epithelial ovarian cancer and are associated with improved outcomes in comparison with patients with BRCA wild-type ovarian cancer,” Gonzalez Marin said. “(Zejula) has shown efficacy in tumors with and without BRCA mutations, and the efficacy and safety of (Zejula) in patients with BRCA-mutated ovarian cancer was assessed in the PRIMA, NOVA and NORA trials.”

In particular, patients in the PRIMA trial had newly diagnosed advanced ovarian cancer and responded to first-line platinum-based chemotherapy. Patients in the ENGOT-OV16/NOVA and NORA trials had platinum-sensitive, recurrent ovarian cancer.

Of the 526 patients in all three trials, the most common mutation was in BRCA1, accounting for 60.6% to 80% of BRCA mutations.

Zejula derived a significant progression-free survival (time during and after treatment when the patient lives without disease progression) benefit compared with placebo in patients with BRCA mutations from all three trials. No differences were observed in the PRIMA trial in patients with BRCA1 and BRCA2 mutations.

Hematological side effects of any severity emerging from treatment occurred in at least 20% of patients assigned Zejula. This was also seen for nonhematological side effects from the treatment of any grade.

“The most common treatment-emergent (side effects) of any grade were thrombocytopenia (low blood platelet count), anemia, neutropenia (low neutrophil counts) and nausea across all three trials,” Gonzalez Martin said during the presentation. “The most common (severe or life-threatening) hematological treatment-emergent (side effects) were thrombocytopenia, anemia and neutropenia.”

For nonhematological treatment-emergent side effects, the most common of any severity included nausea, constipation and fatigue, all of which were mainly minor, Gonzalez Martin said.

“Importantly, no new safety signals were identified,” Gonzales Martin concluded.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Image of a man with brown hair.
Image of a woman with short brown hair and glasses.
Image of a woman with short brown hair and glasses.
Image of a man with brown hair and a suit and tie.
Image of a woman with brown bobbed hair with glasses.
Image of Dr. Minesh Mehta at ASCO 2024.
Image of a woman with blond hai
Image of a man with rectangular glasses and short dark hair.
Image of a man with dark hair wearing a suit with a light blue tie.
Related Content
Illustration of a woman with short gray hair, wearing rectangular-framed glasses.
November 19th 2024

My Top 10 List for Living With Cancer

Kelly Irvin
Nine years as an ovarian cancer “lifer” yields these tips for surviving and thriving when there’s no end of treatment ahead.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of ovaries.
October 30th 2024

Current Treatment May Be Superior to Recentin In Ovarian Cancer

Spencer Feldman
Treatment containing Recentin demonstrated clinical benefits, but it proves worse than the current standard care treatment.
Shannon Miller smiling at a podium while delivering the keynote address at the 2023 Extraordinary Healer event | Image credit: © ATA-GIRL PHOTOGRAPHY
May 4th 2023

Olympian Shares Her Cancer Experience: ‘Give Yourself Grace’

Brielle Benyon
Olympic gymnast, Shannon Miller, sat down with CURE® to discuss her experience with a rare type of ovarian cancer, and how her competitive mindset helped her through.
Image of a DNA strand and "Clinical Trial Corner"
October 8th 2024

First Patient With Ovarian Cancer Receives Peptide-Drug Conjugate in Study

Darlene Dobkowski, MA
This trial is assessing CBX-12 as a potential treatment for ovarian cancer, with additional studies to be conducted in other solid tumor types.
Image of Ann Wilson with sister Nancy Wilson - Jamie McCarthy via Getty Images
September 27th 2024

Ann Wilson of Heart Returns After Chemo, Ryan Reynolds Visits Young Patient and More

Alex Biese Ashley Chan
From Ann Wilson’s return to Heart after chemotherapy to Ryan Reynolds visiting a fan with cancer, here’s what’s happening in the oncology space this week.